StockNews.com Begins Coverage on Cara Therapeutics (NASDAQ:CARA)

Stock analysts at StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a note issued to investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

Shares of NASDAQ CARA opened at $0.46 on Monday. The company has a 50-day moving average price of $0.30 and a 200-day moving average price of $0.32. The stock has a market capitalization of $25.43 million, a P/E ratio of -0.26 and a beta of 0.64. Cara Therapeutics has a 1 year low of $0.23 and a 1 year high of $1.15.

Institutional Trading of Cara Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Disciplined Growth Investors Inc. MN grew its holdings in Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 120,660 shares in the last quarter. FMR LLC boosted its holdings in Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 32,789 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Cara Therapeutics in the third quarter valued at about $29,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.